Search details
1.
CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line.
J Transl Med
; 22(1): 329, 2024 Apr 03.
Article
in English
| MEDLINE | ID: mdl-38570798
2.
Circulating Cancer-Associated Macrophage-like Cells as a Blood-Based Biomarker of Response to Immune Checkpoint Inhibitors.
Int J Mol Sci
; 25(7)2024 Mar 28.
Article
in English
| MEDLINE | ID: mdl-38612563
3.
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.
Cancer Immunol Immunother
; 71(4): 865-874, 2022 Apr.
Article
in English
| MEDLINE | ID: mdl-34462870
4.
The role of opioids in cancer response to immunotherapy.
J Transl Med
; 19(1): 119, 2021 03 23.
Article
in English
| MEDLINE | ID: mdl-33757546
5.
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort.
J Transl Med
; 19(1): 270, 2021 06 24.
Article
in English
| MEDLINE | ID: mdl-34167578
6.
Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient?
Curr Oncol Rep
; 23(12): 147, 2021 11 08.
Article
in English
| MEDLINE | ID: mdl-34748099
7.
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence.
J Cell Physiol
; 235(11): 7900-7910, 2020 11.
Article
in English
| MEDLINE | ID: mdl-31943171
8.
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
Int J Cancer
; 146(7): 1917-1929, 2020 04 01.
Article
in English
| MEDLINE | ID: mdl-31330065
9.
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Cancer Immunol Immunother
; 69(11): 2209-2221, 2020 Nov.
Article
in English
| MEDLINE | ID: mdl-32474768
10.
Thyroid disorders in programmed death 1 inhibitor-treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor?
Clin Endocrinol (Oxf)
; 92(3): 258-265, 2020 03.
Article
in English
| MEDLINE | ID: mdl-31788837
11.
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice.
J Transl Med
; 17(1): 376, 2019 11 15.
Article
in English
| MEDLINE | ID: mdl-31730009
12.
Correspondence on 'Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation' by Braaten et al.
Ann Rheum Dis
; 81(1): e13, 2022 01.
Article
in English
| MEDLINE | ID: mdl-31907163
13.
Prolactin as a Potential Early Predictive Factor in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
Oncology
; 93(1): 62-66, 2017.
Article
in English
| MEDLINE | ID: mdl-28407622
14.
Antinuclear antibodies may predict the development of immune-related adverse events in asymptomatic patients treated with immune checkpoint inhibitors: results from a single-center cohort.
Clin Exp Med
; 24(1): 72, 2024 Apr 10.
Article
in English
| MEDLINE | ID: mdl-38598028
15.
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.
Eur J Cancer
; 202: 114006, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38489861
16.
Evaluation of Efficacy of ALK Inhibitors According to Body Mass Index in ALK Rearranged NSCLC Patients-A Retrospective Observational Study.
Cancers (Basel)
; 15(13)2023 Jun 30.
Article
in English
| MEDLINE | ID: mdl-37444532
17.
Rheumatic Diseases Development in Patients Treated by Anti-PD1 Immune Checkpoint Inhibitors: A Single-Centre Descriptive Study.
Life (Basel)
; 13(4)2023 Mar 25.
Article
in English
| MEDLINE | ID: mdl-37109406
18.
Circulating Natural Killer Cells as Prognostic Value for Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Correlation with Sarcopenia.
Cancers (Basel)
; 15(14)2023 Jul 12.
Article
in English
| MEDLINE | ID: mdl-37509255
19.
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials.
Crit Rev Oncol Hematol
; 192: 104190, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37871779
20.
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer.
Clin Cancer Res
; 29(14): 2714-2724, 2023 07 14.
Article
in English
| MEDLINE | ID: mdl-37125965